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Abstract
The challenge of distinguishing genetic drift from selection remains a central focus of population genetics. Time-sampled
data may provide a powerful tool for distinguishing these processes, and we here propose approximate Bayesian, maximum
likelihood, and analytical methods for the inference of demography and selection from time course data. Utilizing these
novel statistical and computational tools, we evaluate whole-genome datasets of an influenza A H1N1 strain in the presence
and absence of oseltamivir (an inhibitor of neuraminidase) collected at thirteen time points. Results reveal a striking
consistency amongst the three estimation procedures developed, showing strongly increased selection pressure in the
presence of drug treatment. Importantly, these approaches re-identify the known oseltamivir resistance site, successfully
validating the approaches used. Enticingly, a number of previously unknown variants have also been identified as being
positively selected. Results are interpreted in the light of Fisher’s Geometric Model, allowing for a quantification of the
increased distance to optimum exerted by the presence of drug, and theoretical predictions regarding the distribution of
beneficial fitness effects of contending mutations are empirically tested. Further, given the fit to expectations of the
Geometric Model, results suggest the ability to predict certain aspects of viral evolution in response to changing host
environments and novel selective pressures.
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Introduction
Influenza A virus (IAV) is an important human pathogen,
resulting in approximately 36,000 deaths annually in the United
States [1] and eliciting constant concerns regarding the spread of
new pandemic strains [2–4]. IAV is an eight segment RNA virus
that can rapidly evolve owing to a high mutation rate [5], genomic
reassortment [6], and stochastic migration of virus from isolated
human populations [7] or animal reservoirs [8]. The most
common therapies for IAV infections include neuraminidase
inhibitors, including the widely used oseltamivir. Oseltamivir was
initially designed based on structural information [9], and has
been shown to be a competitive inhibitor of the neuramindase
active site [10]. Due to the mechanism of action of oseltamivir, it
was widely believed that the evolution of drug resistance would
decrease fitness of the virus and therefore, be unlikely to be of
importance in a clinical setting [11]. However, oseltamivir
resistance has been shown to evolve quickly in human hosts
[12,13] and pandemic H1N1 IAV isolates developed resistance to
the drug [14]. The most common resistance mutation of H1N1
strains is the H275Y mutation (N2 numbering) which is located
near the neuraminidase active site and attenuates oseltamivir
binding [10]. The recent rise of oseltamivir resistance in clinical
isolates is likely due to the presence of compensatory mutations in
the neuraminidase (NA) and hemagglutinin (HA) genes that
increase the fitness of the H275Y resistance mutant [15–17].
Here, we describe the analysis of IAV populations during the
evolution of drug resistance during in vitro growth. This system
offers an ideal platform to study the relative effects of genetic drift
and selection in evolution, as a target of selection, specifically the
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H275Y mutation, is known prior to analysis. Further, in vitro
growth platforms allow for the control and knowledge of
demographic parameters, particularly the severity of population
bottlenecks – thus allowing insight into the expected role of genetic
drift. Lastly, the high mutation rate and short generation time of
IAV allows for adaptation to occur on experimentally tractable
time scales.
This experimental set-up allows for an additional benefit –
namely, time-sampled whole-genome data. This added temporal
dimension provides an important component in the puzzle of
disentangling selection and demography – as it becomes possible
to utilize analytical results describing the change in frequency [18]
and sojourn time [19] of beneficial mutations. Thus, time-sampled
data allow the trajectory of any individual allele to be used to
better identify the action of natural selection, rather than simply
the patterns of genomic variation as utilized by standard single
time-point site-frequency spectrum based statistics [20].
Utilizing this experimental approach and the above reasoning,
we have tested and developed novel statistical tests of selection for
time-sampled population data. We infer effective population size
(Ne) in this platform, and develop novel analytical-, maximum
likelihood-, and approximate Bayesian -based approaches to
determine the contributions of genetic drift and selection in this
biological system. Finally, based on this population genetic
inference, we demonstrate that IAV development of drug
resistance follows the expectations of Fisher’s Geometric Model,
offering a novel approach to predicting viral evolution in response
to changing host environments and novel selective pressures.
Results and Discussion
Influenza A/Brisbane/59/2007 (H1N1) was initially serially
amplified on Madin-Darby canine kidney (MDCK) cells for three
passages. The samples were then passaged either in the absence of
drug, or in the presence of increasing concentrations of
oseltamivir, a neuraminidase inhibitor (Figure 1). At the end of
each passage, samples were collected for whole genome high
throughput population sequencing providing a high depth of
coverage. In addition, biological replicates of the entire experi-
ment were performed and analyzed. We first focus on one of the
two experiments in the following results, and then use the replicate
as a point of comparison. The genetic diversity calculated as the
average expected heterozygosity [21] in each passage was very
low, stable throughout the entire experiment, and slightly lower
during oseltamivir treatment (6.261024 vs. 4.561024, see Figure
S1). The frequency spectra indicated that most single nucleotide
polymorphisms (SNPs) were segregating at low frequency and the
shape was comparable at P4 and P12 (Figure S2). The number of
new mutations accumulated within each passage was limited and
very rarely reached high frequencies, in particular in the presence of
oseltamivir, suggesting that the viral populations were under severe
purifying selection. As a consequence, nearly all observed SNPs
were biallelic: over all passages and nucleotides, the frequency of the
third allele was 0.02% on average, with a 99% quantile of 0.1%. For
this reason, we considered all SNPs as biallelic in our subsequent
analyses. Finally, we observed 4 and 7 newly arising mutations
reaching a frequency of more than 50% during our experiment in
the absence and presence of oseltamivir, respectively.
Expected impact of drift and ascertainment
The effective population size Ne determines how efficiently
natural selection acts on a population [18]. A beneficial mutation
Figure 1. Experimental set-up. IAV was adapted from chicken egg
to MDCK cells (passages 1–3) and then serially passaged in MDCK cells
in the presence (red) or absence (white) of escalating concentrations of
oseltamivir (passages 4–12) in replicate experiments.
doi:10.1371/journal.pgen.1004185.g001
Author Summary
In recent years, considerable attention has been given to
the evolution of drug resistance in the influenza A H1N1
strain. As a major annual cause of morbidity and mortality,
combined with the rapid global spread of drug resistance,
influenza remains as one of the most important global
health concerns. Our work here focuses on a novel multi-
faceted population-genetic approach utilizing unique
whole-genome multi-time point experimental datasets in
both the presence and absence of drug treatment. In
addition, we present novel theoretical results and two
newly developed and widely applicable statistical meth-
odologies for utilizing time-sampled data – with a focus on
distinguishing the relative contribution of genetic drift
from that of positive and purifying selection. Results
illustrate the available mutational paths to drug resistance,
and offer important insights in to the mode and tempo of
adaptation in a viral population.
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has a greater chance to be successful in large populations
compared to small populations, where allele frequency changes
are mainly impacted by genetic drift. Therefore, the fate of a
beneficial allele is determined by both the effective population size
Ne and the selection coefficient s. For this reason, observing an
allele increasing in frequency cannot be considered as a direct
evidence of natural selection. Neutral and deleterious mutations
may also increase in frequency, but simply with a lower probability
[19]. The problem of distinguishing drift from selection is
exacerbated in genome-wide studies, as these low probability
events are more likely to occur among the large number of sites
considered. Figure 2 illustrates this point, simulating a Wright-
Fisher haploid model with selection intensities matching those
inferred in the data set. We plot eight randomly drawn trajectories
starting from a single mutant and conditioned on reaching at least
a frequency of 10% in one of the passages (for Ne = 100 (Figures 2A
and 2B) or Ne = 1000 (Figures 2C and 2D), and s = 0 (Figures 2A
and 2C) or s = 0.1 (Figures 2B and 2D)). In the absence of
selection, in populations of low effective size (Ne = 100), the relative
frequency of mutants reaching a frequency of 10% or higher is
elevated (5.6% of the simulations) compared to Ne = 1000 (0.7% of
the simulations). With selection (s = 0.1), these values are nearly
unchanged if the population is small (6% vs. 5.6% for Ne = 100), as
low frequency mutants are mostly affected by drift in this scenario.
However, values increase dramatically as the effective population
size increases (4.1% vs. 0.7% with Ne = 1000). Finally, the
simulated advantageous mutations follow almost deterministic
trajectories in large populations (Figure 2D) while drift is still
affecting them strongly when Ne = 100 (Figure 2B), eventually
leading to the loss of the mutant.
Figure 2. Simulated Wright-Fisher trajectories illustrating the impact of effective population size, selection strength, and
ascertainment. We simulated a Wright-Fisher haploid model with selection matching our data set (same number of generations (i.e., 13 per
passage), and selection beginning at passage 4). We plot eight randomly drawn trajectories starting from a single mutant and conditioned on
reaching at least a frequency of 10% in one of the time points. We used an effective population size of Ne = 100 in A and B, or Ne = 1000 in C and D.
The relative fitness of the new mutation was set to 1+s, with s = 0 in A and C, or s = 0.1 in B and D. The fraction of simulations reaching our 10% allele
frequency condition is given above each panel in parentheses.
doi:10.1371/journal.pgen.1004185.g002
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Estimating Ne and selection
Several methods have been proposed to estimate the effective
population size (Ne) from time-sampled data assuming neutrality.
Moment-based methods [22–25] have the advantage of being
computationally efficient as compared to likelihood-based methods
and thus can accommodate large genomic data [26–29], and can
provide similar accuracy when using appropriate estimators [30].
Likelihood methods have the advantage of being able to also take
into account the effects of selection, and a handful of methods have
recently been proposed to estimate both Ne and selection
coefficients [18] from time-sampled data [31–33]. However, being
based on diffusion approximation [34], they assume large effective
population sizes and low selection coefficients. Goldringer and
Bataillon [35] proposed to use a moment-based estimator of Ne to
reject neutrality based on Wright-Fisher simulations, but currently
there is no available method able to co-estimate Ne and s in this
context. In particular one would like to use the information shared
by all loci to estimate Ne, and to estimate s at each locus. Here we
use Fs9, an unbiased estimator of Ne proposed by Jorde and Ryman
[30] and extend the idea proposed by Goldringer and Bataillon
[35] to also estimate s using an Approximate Bayesian Compu-
tation (ABC) approach [36] (see Materials and Methods). Our
method does not rely on diffusion approximation, is appropriate
for small effective population sizes and large selection coefficients,
and is computationally efficient to scale with our genomic data.
For both experiments with and without oseltamivir, we
respectively estimated Ne to be 226 (99% highest posterior density
(HPD) interval: [210;257]) and 176 (99% HPD interval:
[117;256]). These low effective population sizes are in line with
the values estimated from natural populations in IAV and other
viruses [37–39]. They can partially be attributed to the severe
bottlenecks introduced at each passage, followed by exponential
population growth. For comparison, we also calculated the
expected effective population sizes as the harmonic mean of
census sizes at each generation [40]. We used the estimated census
population sizes measured at the beginning of each passage
(Table 1) and assumed an exponential population growth to 106
virions during each of the 13 generations. We obtained values of
696 and 737 in experiments with and without oseltamivir,
respectively. As expected, this illustrates the strong influence of
the bottlenecks despite the very large population sizes assumed
(106) at the end of each passage. However, the bottlenecks alone
cannot explain the even lower effective population sizes estimated
from the full genomic data, though the large variance in burst size
(i.e. the number of virions produced per infected cell) [41,42] is
also of relevance [40].
We then obtained posterior distributions of s for all contending
mutations (i.e., mutations that were not lost by drift and are
segregating in the population in at least one time point). Neutrality
was rejected when the posterior density interval of s excluded zero
(i.e., P(sv0Dx)v0:01), defining Bayesian ‘p-values’ [43]. These p-
values are plotted for all sites in the genome in Figure 3A and 3C.
Note that there are fewer sites in the presence of oseltamivir (82 vs.
405, see Figure 3C and 3A) as fewer time points match the criteria
defining contending mutations. We plot the trajectories corre-
sponding to the significant sites in the absence and presence of
drug respectively in Figure 3B and 3D. Despite the reduced data
size, more sites are found to be under selection in the presence of
oseltamivir (8, representing almost 10% of the sites considered;
versus 4, representing less than 1% of the sites in the absence of
drug), and having larger selection coefficients (0.15 on average vs.
0.08). In addition, an HA mutation (HA 1395 encoding a D112N
mutation in HA2) was positively selected in both the absence and
presence of drug, suggesting that it likely represents a tissue culture
adaptation. However, the mutation was nonetheless more strongly
beneficial in the presence of drug (s= 0.22 vs. s= 0.12, see
Figure 3B and 3D).
The known H275Y resistance mutation [10] located on the NA
protein at position 823 in the RNA sequence goes rapidly to
fixation in the presence of oseltamivir (Figure 3D) with a point
estimate of s = 0.15. The corresponding posterior distribution is
represented in Figure 4 along with the ABC correlation plot. The
separate correlation between s and the two statistics Fsd9i and Fsi9i
is also shown in Figure S3. In the presence of drug, NA and HA
are the two segments containing the mutations with the highest
selection coefficients (0.20 on average, compared to 0.11 for the
other segments). This finding is in accordance with recent results
showing that mutations in HA compensate for the deleterious
effect (low growth capacity) of H275Y [17]. We extracted from the
NCBI Influenza Virus Resource database [44] the recent changes
in allele frequency of the 12 candidate sites under selection in
natural populations of H1N1 (Figure S4). Two out of 12
candidates increased rapidly in frequency in the past five years.
As previously reported [14], H275Y started to increase in
frequency in the 2007/2008 influenza season and almost reached
fixation in 2009/2010 (90.1%). A synonymous mutation in
segment NS at position 820 (F116) also increased very rapidly in
frequency in 2005/2006 (92.6%), decreasing again to less than
12% in the following years to finally reach fixation in 2009/2010.
We randomly simulated 1000 pseudo-observed data sets to cross
validate our ABC approach with parameters inspired by the drug-
treated experiment. We used the same number of loci with
selection coefficients s taken from the obtained posterior mean,
Ne = 176, a sample size of 1000 and initial allele frequencies of 1/
Ne. For each simulated replicate, we estimated Ne and s using our
proposed ABC approach (see Materials and Methods). This
simulation represents a ‘‘worst-case’’ scenario, as the impact of
genetic drift is strong and allele frequencies are skewed. Despite
this, we found that the accuracy is generally very good (Figure S5A
and B). We note that as the trajectories start from a single mutant,
it is difficult to distinguish negative selection from neutrality, both
generally leading to a rapid loss of the mutant and to a wide
posterior for s with a mean around zero. The same phenomenon is
also observed for beneficial mutations, but at a lower frequency.
The problem vanishes when the initial allele frequency is
increased, or in larger populations (data not shown).
Table 1. Bottleneck sizes at each passage.
Passage 1 2 3 4 5 6 7 8 9 10 11 12
Without oseltamivir 48 43 2575 255 85500 8600 27750 4725 37 92 2102 31
With oseltamivir 48 43 2575 255 49250 8600 7300 4800 19 75 2075 42
Population size estimated at the beginning of each passage in the absence or presence of oseltamivir (see Figure 1).
doi:10.1371/journal.pgen.1004185.t001
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Finally, we evaluated whether our model based on constant
effective population size is robust to the series of bottlenecks and
population expansions induced at each passage in the experiment
(see Table 1). Ewens [45] showed that in a population with a size
changing cyclically over time, the probability of fixation of an
allele is approximately the same as in a population of constant size
with Ne =N*, where N* is the harmonic mean of the population
sizes at each generation, which is also the effective population size
of the fluctuating population. To evaluate this finding in the
context of our estimation procedure, we simulated 1000 additional
data sets with varying population sizes. In order to match the drug-
treated experiment, 9 passages of 13 generations each were
simulated, with exponential population growth from N=23 to
N=106 (see Figure 1). The founding population size (N=23) was
chosen as it results in a harmonic mean of Ne = 176 for the 13
generations (i.e., the empirically estimated value from the
experiment). Here again, this corresponds to a ‘‘worst-case’’
scenario where the bottleneck at each passage is extremely strong
(see Table 1 for the true data) and population expansion very
rapid. We found that our ABC procedure based on a constant
effective population size indeed accurately estimates Ne and s
(Figure S5C and D) - with Ne being slightly downwardly biased
(estimated to 167 on average), and large selection coefficients are
very slightly upwardly biased.
Effect of genetic linkage
Linkage between selected and neutral sites can confound
inference when estimating genome wide selection coefficients.
Further, the frequency of homologous recombination in the IAV
genome is still debated [46]. If absent, we expect to observe strong
effects of genetic hitchhiking [47], where linked sites should
increase in frequency together with selected sites due to physical
linkage. However, the very low genetic diversity in our populations
limits this phenomenon, and we identified at most two selected
sites within the same segment. We also note that the initial allele
frequencies of the sites under selection are very low in all cases
Figure 3. Evidence of positive selection in the H1N1 genome in the absence and presence of oseltamivir.We plot the Bayesian P-values
for each SNP in log scale in the absence and presence of oseltamivir in A and C, respectively. The horizontal red lines are genome-wide significance
thresholds of P = 0.01. The eight segments are separately color-coded, a scheme which is maintained in all panels. Significant nonsynonymous
mutations are represented with triangles. We plot the minor allele frequency trajectories of all significant SNPs over the experiment in the absence
and presence of oseltamivir in B and D, respectively. The vertical dotted red line indicates the time of the oseltamivir addition (see Figure 1).
Trajectories are represented in dashed lines if a second SNP was significant within a given segment. For each significant SNP, the name of the
segment, the position of the SNP, the nucleotide increasing in frequency, and the estimated selection coefficients with our Ne-based ABC method are
indicated in the top left corner of B and D. In E, we represent the 3D structure of the proteins corresponding to the segments coding for membrane
proteins (for those with a resolved structure). We indicate the amino acid residues corresponding to the significant mutations with arrows. The SNP
locations highlighted on the structures are as follows: HA2 D112N (nonsynonymous), NA G193G (synonymous), H275Y (nonsynonymous), and M1
A41V (nonsynonymous). Although the M segment encodes both the M1 and M2 protein, the significant SNP is only positioned in the coding region
of M1. The significant SNP in the NS segment (F116) is synonymous and only positioned in the region coding for the NS2 protein. HA is represented
as a trimer, with the significant residue being highlighted (red) in each monomer, though one residue is slightly obscured due to being buried in the
protein complex. NA and M1 are represented as monomers, and NA is shown with a bound molecule of oseltamivir.
doi:10.1371/journal.pgen.1004185.g003
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(Table 2) and below our detection threshold (0.17%) in 11 out of
the 12 cases. This suggests that selection is primarily acting on de
novo mutations rather than on standing variation in our
experiment.
Only two trajectories in each experiment were identified as
having a poor fit to the assumed Wright-Fisher model, and are
shown in Figure S6. Figure S7 also shows the ABC correlation and
posterior plots for one of these cases, where one can see the
inability of the model to generate simulations similar to the
observed data. Clonal interference (i.e., the competition of
simultaneously segregating beneficial mutations) has recently been
proposed to play an important role in influenza evolution [48] and
could explain such patterns, in which, in the absence of
recombination, an initially steep trajectory becomes halted or
even reversed by the appearance of another more beneficial
mutation (as in Figure S6A). However, given the small effective
population sizes in this experiment, it is not surprising that we do
not observe more such trajectories, as the probability that multiple
contending beneficial mutations are present at a given point is
small [49]. Integrating the potential of clonal interference into the
methodology developed here will be the subject of future study.
Replicated experiment
The experiment was replicated starting at passage 4 (Figure 1),
and analyzed with our Ne-based ABC method. We plot the
Bayesian p-values for all sites in the genome in Figure S8A and
S8C and the trajectories corresponding to the significant selected
sites, in the absence and presence of drug, in Figure S8B and S8D,
respectively. More details are given on selected sites in Table S1.
Consistent with the first experiment, more sites are identified as
being under selection in the presence of oseltamivir (6 vs. 2). The
H275Y resistance mutation appears only at passage 9 and also
increases very rapidly in frequency in the presence of oseltamivir
(Figure S8D) with an even higher selection coefficient s = 0.27.
Interestingly, like in the first experiment, one nonsynonymous HA
mutation (position 1211, encoding a N50K mutation in HA2) is
under strong selection in both the absence and presence of
oseltamivir, and is located only 184 base pairs from the one
identified in the first experiment (position 1395, encoding a
D112N mutation in HA2). Similarly, a nonsynonymous mutation
in segment M at position 92 (encoding an E23Q mutation of the
M1 protein) is also under selection (s = 0.06), where in the first
experiment, one was identified at position 147 (encoding an A41V
mutation of the M1 protein, s = 0.08).
Likelihood and coalescent based estimation
As a matter of comparison, for each significant trajectory
identified using our Ne-based ABC method, we applied a diffusion
approximation likelihood-based method [32] which we here
extend to a haploid model. For the H275Y mutation, the two-
dimensional likelihood surface for c=Ne
.s and the age of the
mutation (t0) is shown in Figure 5. The selection coefficients
obtained are mostly consistent between the two methods and are
given in Table 2. They tend to be different when the trajectories
have an unexpected behavior under the Wright-Fisher model, like
the synonymous PB1 mutation at position 33 (K11), also identified
as having a poor fit to our model. In this case the behavior of the
two methods is hard to interpret. Likelihood-based methods in
general should be more accurate than ABC methods, which
reduce the whole data in to a few summary statistics. However, as
stated previously, the diffusion approximation made to calculate
the likelihood in this method is not appropriate for high selection
coefficients and low effective population sizes (i.e., it is appropriate
for Nes,1). As expected, this method tends to over-estimate s
compared to our ABC method when s is large. Indeed, in this
approximation, drift is a slow process and very large allele
frequencies changes as we observe can only be explained by
excessively large values of s. Additionally, there is currently no
available likelihood method that can integrate the information
shared by all sites to infer Ne, and estimating Ne from a single site is
particularly inefficient [32]. For this reason, and to have a fair
comparison, we did not attempt to estimate Ne here, but fixed it to
Figure 4. Ne-based Approximate Bayesian Computation for the H275Y resistance mutation in the presence of oseltamivir. For 10’000
simulated trajectories (out of the 100’000 simulations performed), we plot in A the values of the statistics Fsi9 and Fsd9 with colors corresponding to
the selection coefficients s, as well as the values calculated for the real trajectory of the H275Y oseltamivir resistance mutation in black. We indicate
the region corresponding to the best 1% retained simulations with a dashed line, and plot the corresponding two-dimensional posterior distribution
for s and Ne in B.
doi:10.1371/journal.pgen.1004185.g004
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the value estimated above via the ABC approach. Finally, we note
that this class of method is computationally intensive and cannot
practically be applied to whole-genome datasets.
In addition, we have developed a new coalescent-based method
that explicitly models the known demography of our experimental
populations for comparison (Table 1). This approach has the
additional advantage of incorporating the genetic diversity linked
to the beneficial mutation into the estimation procedure, allowing
us to estimate the mutation rate and refine estimates of s. Figure 6
shows the combination of selection coefficient (s= 0.12) and
mutation rate (m<1027) with the highest likelihood for the H275Y
mutation. Interestingly, the estimation obtained with these
simulations accounting for the true demography is consistent with
our Ne-based ABC method, which gives a posterior mean for the
selection coefficient of s = 0.15 (Table 2 and Figure 4).
It is noteworthy that the three methods here developed and
applied to this data are complementary, and thus have been used
jointly. Our Ne-based ABC approach is computationally efficient,
can be applied to large genomic datasets, and does not rely on
diffusion approximation. It provides both estimates of Ne using
information from the whole genome, and posterior distributions
for s at each individual site. Using these results, it is next interesting
to utilize the likelihood-based method, as it can be more accurate
for small s (or in cases where Ne is large), as it uses the full data
rather than summary statistics. Additionally, it can estimate the
age of the beneficial allele, which can be of interest in some cases.
Being more computationally intensive, one can apply it on the
candidate sites identified by the Ne-ABC method, and even take
advantage of the estimated Ne that it provides. Finally, our new
coalescent method is a promising first attempt to estimate s not
only using a single allele frequency trajectory, but the whole
sequence linked to it. It is also computationally very intensive and
can be used on top candidate sites to refine the posterior
distributions obtained from the Ne-based ABC method.
Fisher’s Geometric Model and distance from optimum
Further utilizing these estimated per-site Ne-based selection
coefficients, and in order to contextualize these results, we utilize
the framework of Fisher’s Geometric Model (FGM). The FGM
[50] predicts that environmental challenges increase the distance
between the current phenotype and the phenotypic optimum,
thereby allowing for more and stronger beneficial mutations.
Here, the oseltamivir environment represents a novel (and
challenging) environment, which is expected to result in a shift of
the optimum away from the location of the current population.
This is reflected both in a higher maximum beneficial selection
coefficient (0.288 vs. 0.117) and in a higher mean beneficial
selection coefficient (0.026, bootstrap bias-corrected and acceler-
ated [51] 95% confidence interval (CI): [0.017; 0.039] vs. 0.016,
95% CI [0.015; 0.017]), obtained from the point estimates
obtained using the Ne-based ABC approach - indicating that the
optimum may be indeed further away from the current phenotype
in the drug as compared with the no-drug environment.
In order to study the distribution of fitness effects (DFE)
observed, and to quantify the distance to the phenotypic optimum
in each environment, we chose three different biologically relevant
distributions to be fitted to the data. Since we were particularly
interested in the distance to the phenotypic optimum, we used the
displaced-gamma distribution proposed by Martin and Lenor-
mand [52], which results in an approximately beta-shaped DFE of
beneficial mutations [53], and allows for a direct estimate of the
distance to the optimum under the FGM. Secondly, we used a
half-normal distribution, which is predicted from the FGM, when
the optimum is (infinitely) far away. Third, we used the generalized
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Pareto distribution (GPD). Given that beneficial mutations are so
rare that they represent the tail of the full DFE, the GPD allows for
the estimation of the most likely extreme value domain [54]. In
other words, the resulting estimate of the shape parameter k yields
information on whether the DFE is bounded (i.e., the full DFE
belongs to the Weibull domain), whether its tail is exponential-like
(Gumbel domain), or whether the tail is heavier than exponential
(Frechet domain). In terms of the underlying biology, this is a very
important question: for example, a bounded DFE would indicate
that mutations cannot exceed a certain effect size, whereas, on the
contrary, a heavy-tailed DFE would suggest that mutational effect
sizes are highly unpredictable. Supporting arguments have been
made for an exponential tail being the most biologically reasonable
[55], and related studies have suggested an exponential distributions
of fitness effects (e.g., [56,57]). However, there also exists empirical
evidence for bounded tails of the beneficial DFE (e.g., [58,59]).
Of note, our data consist not of the full distribution of newly
arising beneficial mutations, but of the fraction of those beneficials
that survive drift and are segregating in the population for at least
a short time (so-called ‘‘contending beneficial mutations’’ [60,61]).
Barrett et al. [60] pointed out that this distribution arises as the full
distribution of new mutations weighted by the (approximate)
probability 1-exp(-2s) that a mutation with selection coefficient s
survives drift. The resulting probability densities for the three
tested distributions are noted in the Materials and Methods.
We fitted all three resulting contending distributions to the data
by numerically maximizing the log likelihood using a weighted
bootstrap approach [62]. All results are reported in Table 3 and
Figures 7 and 8.
In the absence of oseltamivir, the half-normal distribution yields
the highest median log likelihood (cf. Table 3, and Figure S9A),
but the bootstrap estimates show a large variance (also owing to
the lower flexibility afforded by the single parameter). Hence, the
outcome is sensitive to potential measurement error, or sampling
bias. In fact, the 95% confidence intervals of the bootstrap
estimates of both the GPD and the beta distribution lie within that
of the half-normal, indicating that they both may represent equally
good summaries of the true distribution. In the presence of
oseltamivir, the GPD clearly provides the best fit, with both the
half-normal and the scaled beta distribution reaching generally
lower log likelihoods (cf. Figure S9B).
The generally good fit of the GPD provides support for the
assumption that the beneficial portion of the DFE represents a tail
distribution. If this condition is met, the GPD is expected to be the
most flexible among the three tested distributions, because it can
account for all possible tail shapes. Because we observe only the
contending distributions in the present study, the tail of the
distribution becomes even more important, and it must be noted
that the tails of both the beta scaled and the half-normal
distributions studied here are both contained within the GPD.
After establishing that the GPD yielded a good fit to the
observed data, we interpreted the estimated shape parameter k
that determines the extreme value domain of the underlying DFE
(cf. Figure 8). In the absence of oseltamivir, we observe
k=20.0532 (95% CI: 20.0786, 20.0075), indicating that the
full DFE belongs to the Weibull domain of attraction (Figure 8A).
Hence, it has a right-truncated tail, and we estimated the
maximum possible mutational effect as d = 0.17 (95% CI: 0.12,
0.76). We can compare this result with the estimate of the distance
to the optimum obtained from the scaled beta distribution. With
s0 = 0.18 (95% CI: 0.12, 1), this estimate agrees nicely with that
from the GPD. In terms of the underlying biology, this indicates
that there is remaining potential for adaptation also in the absence
of oseltamivir, but that the maximum possible effect size does not
Figure 5. Log-likelihood contours for the H275Y resistance mutation in the presence of oseltamivir. We plot the two-dimensional
likelihood surface for the selection parameter c=Ne
.s (x-axis) and the allele age t0 (y-axis) in generations, with generation zero representing the end
of the experiment. Horizontal black lines represent sampling times. The colors indicate the value of the log-likelihood, with red being the highest and
blue being the lowest. The maximum likelihood is shown as a black dot, and the log likelihood was lowered from its peak by X 22:5%/2 = 2.996, to
construct a 95% confidence (likelihood) region for the parameters (dashed black line).
doi:10.1371/journal.pgen.1004185.g005
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differ greatly from the observed maximum selection coefficient
(s = 0.117).
The pattern looks very different in the presence of oseltamivir.
Here, the estimated shape parameter is k=0.24 (95% CI: 0.14,
0.38), clearly indicating a heavy-tailed DFE that belongs to the
Frechet domain of attraction (Figure 8B). Supporting this finding,
it was not possible to obtain any reasonable estimates of the
distance to the optimum under the scaled beta distribution. This
support for a heavy-tailed distribution is also consistent with recent
results examining the DFE in populations of yeast that have been
subjected to extreme environmental conditions [63].
This finding suggests that the potential for adaptation in the
drug environment is indeed much higher than the highest
observed selection coefficient, and that mutational effect sizes will
be difficult to predict under strong adaptive challenges. In
particular, upon a longer run of the experiment (e.g., over the
course of time in natural populations) even stronger beneficial
mutations than those identified in the present experiment could be
expected (however, it is noteworthy that the H275Y mutation
appears to be re-identified across multiple different experiments, as
discussed below). In comparison, there is only little potential for
adaptation in the no-drug environment. However, the optimum is
still far as compared with other examples from the literature [64],
which could indicate ongoing adaptation to the MDCK cells. We
note that we do not explicitly model experimental errors in our
analyses, as this would require several replicated experiments
[54,56]. However, the heavy tail of the DFE in the presence of
oseltamivir (Figure 7B) may indeed be influenced by such factors,
and this result should thus be interpreted with caution.
Biological implications
Lastly, we attempted to interpret these results in light of the
known biology of influenza (Figure 3E). The NA mutation H275Y
is a well-characterized oseltamivir-resistance mutation and has
been shown to alter the hydrophobic pocket of the NA active site,
thereby reducing affinity for drug [10,65–69]. Thus, re-identifica-
tion of this substitution aids to validate the results. Further, A41V
(encoded by a C147T SNP) and E23Q (encoded by a G92C SNP)
substitutions of the M1 protein were identified in the first and
second experiments, respectively. The location of these mutations
(helices 3 and 2) are not overlapping with regions important for
RNA or membrane binding, which facilitate virion assembly and
maintenance of virion integrity. In addition, the location of either
residue does not appear to be important for forming extended
sheets of M1 protein, as proposed previously [66]. Therefore, the
role of these mutations in viral fitness in the presence of oseltamivir
may be related to additional roles of the M1 protein. An intriguing
possibility is that interactions between M1 and the NA cytoplasmic
tail important during virion budding [70–72] are altered by the
H275Y mutation and are compensated for by additional
mutations in the N-terminal region of M1 [73]. Two adaptive
substitutions were also observed in the HA2 peptide during growth
in the presence and absence of oseltamivir, with the D112N
(encoded by a G1395A SNP) and N50K (encoded by a C1211A
SNP) substitutions observed in the first and second replicates,
respectively. Interestingly, the trajectories of the substitutions in
the presence of drug appear to be strongly correlated with the rise
of the H275Y mutation (see Figures 3 and S7). The combined
results from the two replicates in the presence and absence of
oseltamivir show that these loci are positively selected during tissue
culture adaptation, and may epistatically interact with the H275Y
allele. The D112N mutation has been well characterized in other
influenza strains and is conserved across all HA serotypes. This
substitution has been shown to cause a rise in the pH of the HA
conformational change and HA-induced endosome and viral
membrane fusion [68,74], a process critical for IAV infectivity
Figure 6. Coalescent-based maximum likelihood surface for the H275Y resistance mutation in the presence of oseltamivir. Two-
dimensional likelihood surface for the selection coefficient (s) (y-axis) and the mutation rate m (x-axis). The graph is colored according to the value of
the log-likelihood (displayed in the embedded legend), where green indicates the highest probability and yellow the lowest.
doi:10.1371/journal.pgen.1004185.g006
Population Genetics of Drug Resistance
PLOS Genetics | www.plosgenetics.org 9 February 2014 | Volume 10 | Issue 2 | e1004185
[75]. Further, the D50K mutation is located in a region known as
the HR1 heptad repeat, interrupting the repeat pattern with a polar-
to-charged residue substitution. The HR1 repeat regions form coiled
coils that undergo conformational changes in low pH conditions and
likewise promote endosomal membrane fusion during IAV infection
[76]. Alterations of endosomal membrane fusion mediated by
mutations in HA2 are a known mechanism for tissue culture
adaptation [77,78], but interactions with a drug resistance allele has
not been described previously. In total, while the results are not
sufficient to confirm this hypothesis, the combined results from
replicate 1 and replicate 2 suggest that epistatic interactions between
M1 and NA, and possibly HA2, may be important during the
selection of drug resistance in IAV populations.
Conclusions
As a major annual cause of morbidity and mortality, influenza
virus infections remain one of the most important global health
concerns. Foremost amongst the challenges in treating this virus
has been its ability to adaptively respond to drug treatment, with
oseltamivir resistance spreading globally during the 2007–2008
and 2008–2009 influenza seasons. In order to evaluate the viral
adaptive response to oseltamivir, we have here developed a multi-
faceted population genetics approach based upon an unparalleled
dataset consisting of whole-genome multi-time point experimental
data both in the presence and absence of treatment. Utilizing
novel approximate Bayesian, likelihood-based, and analytical
results, we identify a handful of known and unknown positively
selected variants, and quantify the distance from phenotypic
optimum imposed by oseltamivir. These results not only confirm a
number of theoretical expectations arising from Fisher’s Geomet-
ric Model and its extensions, but also clearly illustrate the ease by
which resistance may be evolved against neuraminidase inhibitors.
We finally note that the robust methodologies developed here can
be widely applied to time-sampled data from not only experimen-
tal but also natural populations (Figure S4), allowing for the
utilization of a temporal dimension that is highly informative for
identifying the recent action of positive selection.
Materials and Methods
Data generation and bioinformatics
Influenza A virus A/Brisbane/59/2007 (H1N1) from chicken
egg allantoic fluid (NIH Biodefense and Emerging Infectious
Research Resources Repository NIAID, NIH; NR-12282; lot
58550257) was serially passaged in Madin-Darby canine kidney
(MDCK) cells (Figure 1). This strain has the following genome
size: segment 1 (PB2) 2314 nucleotides (nts), segment 2 (PB1)
2302 nts, segment 3 (PA) 2203 nts, segment 4 (HA) 1776 nts,
segment 5 (NP) 1497 nts, segment 6 (NA) 1427 nts, segment 7
(M1/2) 1006 nts, segment 8 (NS1/2) 870 nts. MDCK cells were
maintained in Eagle’s minimal essential medium (MEM) with 10%
fetal bovine serum (Hyclone) and 2 mM penicillin/streptomycin.
Viral infections were performed in influenza virus growth medium
as described [79] and lasted for 72 hours. Virus was continually
passaged on cells to prevent any freeze-thaw cycles and the
amount of virus to initiate a passage and the virus at the end of
each passage were subsequently empirically determined via plaque
assays using standard techniques. These values were used to
determine the bottleneck size (Table 1), MOIs (Table S2),
magnitude of population expansion, and number of doublings
associated with each passage. The number of doublings was used
to determine the number of generations per passage – averaging to
13 generations per passage throughout the experiment, in both the
no drug and drug-treated populations.
For passages indicated in Figure 1, oseltamivir was added at
increasing concentrations and two independent experimental
trajectories were performed. The initial concentration of oselta-
mivir was equal to the ED50, the concentration of drug that
reduced viral plaque numbers to 50% of a no drug control. The
initial ED50 was 0.1 uM (Table S2), indicating that the starting
virus was very sensitive to oseltamivir. The next passage was
performed in the presence of 46ED50. Subsequent passages were
performed by doubling the concentration of oseltamivir if 50%
cytopathic effect (CPE) was observed (i.e., the cytopathic effect in
the cells from the previous passage). If 50% CPE was not observed,
the dose of oseltamivir was reduced to a concentration that lead to
the observation of 50% CPE. Oseltamivir carboxylate
(RO0640802-002; lot 91ST1126/1) was obtained from Roche
(F. Hoffmann-La Roche Ltd, Basel, Switzerland). Concentration
of oseltamivir at each passage can be found in Table S2.
Cell-free virus was obtained at each passage by spinning down
supernatant 72 hour post-infection, and subjected to whole
genome pooled population sequencing. Viral RNA was purified
using the RNeasy 96 Kit (Qiagen, Gaithersburg, MD). Super-
Script III First-Strand Synthesis Supermix (Life Technologies,
Grand Island, NY) and primers that bind the 39 end of all IAV
segments were used for reverse transcription. The cDNA was then
amplified in a single multiplex reaction to amplify all segments of
the genome with near equal efficiency, using primers that have
been described previously. The amplified product was sheared to a
size range of 300–600 base pairs with Fragmentase from New
England Biolabs (Ipswitch, MA) using the procedure recom-
mended by the supplier. DNA was then end repaired, A-tailed,
and ligated to Illumina-compatible adapters containing 6-mer
barcode sequences. The products were size selected by using
0.86 AMPure XP beads (Agencourt, Beverly, MA), collecting
Table 3. Maximum likelihood estimates of the distribution of fitness effects.
With oseltamivir Without oseltamivir
Distribution k1 Log(L) (95% CI)2 s0 (95% CI)
3 Log(L) (95% CI) s0 (95% CI)
GPD 2 180.0 [154.7,199.1] ‘ 1343.3 [1301.5,1374.0] 0.17 [0.12,0.76]
Beta 2 158.8 [122.1,190.0] ‘ 1343.4 [1301.4,1374.1] 0.18 [0.12,1]
Half-normal 1 110.5 [69.3,154.7] ‘ 1375.6 [1274.4,1429.7] ‘
Theoretical distributions of fitness effects fitted to the data.
1Number of parameters.
2Maximized value of the log-likelihood function with 95% confidence intervals.
3Maximum possible effect-size.
doi:10.1371/journal.pgen.1004185.t003
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supernatant and treating with 1.66beads, and eluting DNA with
ddH20. After size selection, DNA was amplified with Illumina PE
PCR primers, quantified and combined into libraries for
sequencing on the HiSeq2000 platform. All sequences used in
this study were generated from 100 base pair reads. All sequence
data is publicly available for download at http://bib.umassmed.
edu/influenza/.
In addition to viral samples, an RNA error control was
generated from a cloned influenza A/Brisbane/59/2007 (H1N1)
NA gene segment. The cloned segment was used as a template in a
T7 transcription reaction to make a pool of control RNA, which
was processed and sequenced in parallel with the viral samples.
Sequence data from the RNA control showed that 95% of erroneous
SNP calls could be eliminated by excluding low frequency (,0.17%)
SNPs. Sequence reads were aligned to Influenza A/Brisbane/59/
2007 reference genome (Genbank accessions CY030232, CY031391,
CY058484–CY058486, CY058488–CY058489, CY058491) using
the BLAST alignment algorithm.
Reads were filtered to eliminate those with Phred quality score
,20 across the read, and the minimum length of the mappable
read .20 nucleotides. The coverage was high with a median over
all passages of 56667 (Table S3 and Figure S10), with 90% of
Figure 7. Distribution of fitness effects. Observed histograms of fitness effects of contending beneficial mutations and the best fit of a
contending generalized Pareto distribution (solid lines) in the absence (A) or presence (B) of oseltamivir. The heavy tail of the DFE in the presence of
the drug is clearly visible.
doi:10.1371/journal.pgen.1004185.g007
Figure 8. Likelihood surfaces for the contending generalized Pareto distribution. Likelihood surfaces of the fit of a contending generalized
Pareto distribution in the absence (A) or presence (B) of oseltamivir. The shape parameter k (on the x-axis) determines the domain of attraction. The
maximum likelihood estimate (indicated by a black dot) lies in the Weibull domain (k,0) in the absence of the drug, indicating a bounded
distribution of fitness effects, whereas it lies in the Frechet domain (k.0) in the presence of the drug, indicating an underlying heavy-tailed
distribution of fitness effects. Black lines represent 25 (A) and 5 (B) orders of log likelihood, respectively. The gray area represents inaccessible
parameter space, because the lower bound of the estimated DFE cannot be lower than the maximum observed selection coefficient. We also show
the distribution of the shape parameter k for the GPD distribution (C).
doi:10.1371/journal.pgen.1004185.g008
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reads mapping. We excluded all sites having coverage lower than
100 and we randomly down-sampled all sites having a coverage
higher than 1’000, to 1’000 in order to estimate allele frequencies
from allele counts. As we almost only observed biallelic SNPs (see
results), for each site we kept only the two alleles having the highest
frequencies over all passages, and called the minor allele as the one
having the lowest frequency at passage 0. In all subsequent
analyses concerning the effect of oseltamivir, we omitted the first
three passages of pre-drug treatment.
Ne-based ABC estimation
The observed data x consists of allele frequency trajectories
measured at L loci: xi(i~1, . . . ,L). We have one parameter Ne
shared by all loci in the genome, and L locus-specific selection
coefficients si(i~1, . . . ,L) that we would like to infer. In a Bayesian
setting, we want to estimate the joint posterior distribution
P(Ne,sDX )!P(X Ds,Ne)P(Ne)P(s)
The likelihood P(X Ds,Ne) can be calculated numerically in some
cases but it relies on approximation and is computationally very
intensive (see below). For this reason, we propose a likelihood-free
approach based on Approximate Bayesian Computation (ABC)
[36,80]. This class of methods is based on Monte Carlo simulations,
which are compared to observed data using summary statistics. In
our model, locus-specific summary statistics capable of estimating s
per locus are needed, as are statistics utilizing information from all
loci jointly in order to infer Ne. However, the standard ABC
algorithm is not usable in such cases, as the probability of obtaining
one simulation with a good match to the observed data for all L loci
simultaneously rapidly tends to 0 as L increases. Recently, Bazin et al.
[80] proposed a new algorithm to overcome this difficulty where the
problem is split in to two steps (Algorithm 2), and we adapt their
general solution to our problem here.
First we note that we can decompose the posterior as
P(Ne,sDX )~P(NeDX )P(sDNe,X )
Using conditional independence (see Appendix in [80]), the joint
density has the factorization
P(Ne,s,X )~ P
L
i~1
P(Xi Dsi,Ne)P(si)
" #
P(Ne)
and the marginal density is
P(Ne,X )~ P
i~1
L
P(Xi DNe)
" #
P(Ne)
where
P(Xi DNe)~
ð
s
P(Xi Dsi,Ne)P(si)ds
Dividing these two densities we have
P(sDNe,X )~
P(Ne,s,X )
P(Ne,X )
~P
i~1
L
P(Xi Dsi,Ne)P(si)
P(Xi DNe)
~P
i~1
L
P(si DNe,Xi)
Finally the joint posterior can be factorized as
P(Ne,sDX )~P(NeDX ) P
L
i~1
P(si DNe,Xi)
and if focused on a particular locus i, we find
P(Ne,si DX )~P(NeDX )P(si DNe,Xi)
This justifies the need for both locus-specific summary statistics
U(Xi) and summary statistics that are a function of all loci together
T(X )~T(X1, . . . ,XL), and we approximate the posterior as
P(Ne,si DX )&P(NeDT(X ))P(si DNe,U(Xi))
The general algorithm to sample from this posterior adapted
from Algorithm 2 in Bazin et al. [80] can be written as:
Step 1. Obtain an approximation of the density
P(NeDx)&P(NeDT(x))
Step 2. For locus i = 1 to i = L
For k= 1 to k=N iterations:
i. Sample Ne from P(NeDT(x))&P(NeDx) generated in step 1.
ii. Sample sk,i from the prior distribution P(s).
iii. Simulate data Xk,i (at locus i only) from P(Xk,i DNe ,s

k,i).
iv. Compute U(Xk,i).
Condition on U(Xi)&U(xi) using ABC to obtain a sample of
observation (Ne ,s

i ) from an approximation to P(si DNe,xi)P(NeDx).
As noted by Bazin et al. [80], if we write the data as x~(xi,x{i)
(where the subscript 2i indicates all data except that from locus i),
x{i is only used once (in the first step) but the second step re-uses
the data xi a second time. The algorithm samples from the correct
posterior distribution only if we use x{i instead of the full data x in
the first step. Otherwise it involves an approximation, which is
valid if we assume that
P(NeDx{i)&P(NeDx{i,xi)~P(NeDx)
The rationale behind this approximation is that when the number
of loci L is large, any given locus i provides a negligible
contribution to the information about Ne (see below).
We now give the details of the two steps of this algorithm. In the
original algorithm [80], the first step is also achieved using ABC.
In our case, we take advantage of having an existing moment-
based estimator of Ne available. This also allows us to avoid the
assumption of independence between loci by using a Bayesian
block bootstrap approach (see below). We define T(X ) as a single
statistic given by Jorde and Ryman Fs9 unbiased estimator of Ne
[30]. For all sites, we calculated Fs9 between consecutive pairs of
time points when the minor allele frequency has reached at least
2% in one observation [30] as:
Fs~
(x{y)2
z(1{z)
and Fs0~
1
t
Fs 1{1= 2~nð Þ½ {2=~n
1zFs=4ð Þ 1{1= ny
  
where x and y are the minor allele frequencies at the two time
points separated by t generations, z~(xzy)=2, and ~n is the
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harmonic mean of the sample size nx and ny at the two time
points. We keep only the sites where we could obtain at least two
values of Fs9 in order to average them over time, and thus obtain
an estimator for each site of the genome used in step 2 below.
Note that in the experiment involving oseltamivir, as only
passages 3 to 12 were considered, a small number of sites
matched this criterion. We also averaged Fs9 values over sites in
order to obtain a genome-wide estimator as in [30]. All Fs9 values
were converted to Ne assuming t= 13 generations per passage and
Ne = 1/Fs9.
A segment-based Bayesian block bootstrap approach [81,82]
was used to obtain a distribution for P(NeDT(X )), as we cannot
assume the independence of sites owing to linkage disequilibrium.
More specifically, as multiple virus infections in cells can lead to
segment reassortment [6], we grouped sites by segment in order to
obtain an estimator for each segment, and randomly resampled
segments with replacement 10’000 times using a Dirichlet prior
[81]. We also checked that the approximation P(NeDx{i)&
P(NeDx) is valid in our case by repeating step 1 for each segment,
where all sites in the considered segment are excluded in order to
account for linkage. We found that the posteriors are very similar
to that obtained using the full data (Figure S11). Ne was only
slightly increased when we excluded the segments carrying the
highest number of beneficial mutations in the presence of
oseltamivir (respectively estimated to Ne = 195 and Ne = 199 when
we excluded HA and NA, compared to Ne = 176 when considering
all segments).
The second step of our method uses the effective size estimated
in the first step as a prior distribution to estimate selection
coefficients (s) at each site in the genome using an ABC approach
[36,80]. For each site, 100’000 time-sampled trajectories were
simulated using a Wright-Fisher haploid model with selection [18]
with three conditions: (i) the trajectories started at the same minor
allele frequency observed at this site [35], (ii) the trajectories match
the same criteria used on the real data to calculate Fs9, and (iii) the
samples are simulated as a binomial sampling using the per-site
sample sizes. For each trajectory, we randomly sample Ne from the
10’000 posterior samples obtained in the first step. The relative
fitness of the beneficial allele was set to 1+s, and we used a uniform
prior for s between 20.1 and 0.5, as we always consider the minor
allele. In the presence of selection, allele frequency trajectories are
expected to be directional, whereas drift introduces random
variance. Being a measure of variance, Fs9 does not incorporate
information about the direction of allele frequency changes. To
integrate this into our estimation procedure, we decomposed Fs9 at
a given site in to two statistics: Fsd9 and Fsi9 calculated respectively
between pairs of time points, where the allele considered is
decreasing and increasing in frequency, such that Fs9=Fsd9+Fsi9.
Using notations of our algorithm presented above, this means that
at each locus i we take U(Xi)~(Fsd
0
i,Fsi
0
i). We retained the best
1% of the 100’000 simulations based on the Euclidian distance
between observed and simulated Fsd9 and Fsi9 statistics in order to
obtain posterior distributions and means for s using a rejection
ABC algorithm [36].
We selected candidate trajectories based on the posterior
distribution obtained for s at each site: we define Bayesian ‘p-
values’ for s as P(sv0Dx) and consider a trajectory to be
‘significant at level p’ if it’s equal-tailed 100(12p)% posterior
interval excludes zero [43]. We also performed a cross-validation
procedure for the ABC method: we randomly simulated 1000
pseudo-observed data sets with parameters inspired by the drug-
treated experiment, with both fixed and varying Ne (see Results).
For each simulated replicated, we estimated Ne and s using our
proposed ABC approach.
We finally identified trajectories for which the Wright-Fisher
model has a poor fit based on the Euclidian distance between our
simulations and the data. Using the cross-validation procedure, we
obtained the null distribution of this distance under the true
model, and used the 99% quantile of the distribution as a
threshold to detect trajectories in our data not fitting the model.
Likelihood-based estimation
The outlier trajectories were selected with the Ne-based ABC
method when the probability of being beneficial was larger than
99%, and used in a likelihood-based method [32] for comparison.
The time-serial method of Malaspinas et al. [32] is an extension of
Bollback et al. [31] to infer the selection coefficient, the effective
population size, and additionally the allele age from temporal allele
frequency data. A Hidden Markov Model (HMM) is used to model
the allele frequency trajectory and an approximate transition density
is applied to compute the likelihood. Here, the method is modified to
fit a haploid model. The diffusion process approximating the Wright-
Fisher haploid model with selection is defined by [34,83]:
L~
1
2
a(y)
d2
dy2
zb(y)
d
dy
a(y)~y(1{y)
b(y)~cy(1{y)
where y is the density of allele frequency at time t in units of Ne
generations and c=Ne?s.
The state space of the HMM are the population allele frequencies
denoted by zi = i/Ne for i~ 0 . . .Nef g. The diffusion process
defining the transition probabilities is approximated with a one-
step process, which only allows the transition to occur between
adjacent states (zi to zi21, zi and zi+1). The infinitesimal generator Q
for the one-step process is a tridiagonal (Ne+1)6(Ne+1) matrix:
Q~
0 0 0    0
d1 g1 b1
0 P P P ...
di gi bi
..
. P P P 0
dNe{1 gNe{1 bNe{1
0    0 0 0
0
BBBBBBBBBBBBB@
1
CCCCCCCCCCCCCA
where bi denotes the rate of jumping from zi to zi+1, di the rate of
jumping from zi to zi21, and gi =bi+di such that 1-gi is the rate of
staying in state zi.
When the approximation of the one-step process is applied, the
solution for the system can be obtained as:
bi~
({1zzi) zi (1zc (zi{zi{1))
(zi{ziz1) ({zi{1zziz1)
and
di~
({1zzi) zi (1zc (zi{ziz1))
(zi{zi{1) (zi{1{ziz1)
The effective population size Ne was set at 176 in the presence of
oseltamivir and at 226 in the absence of drug as inferred by the Ne-
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based ABC method (see Results). For each candidate trajectory,
the maximum likelihood of c and allele age t0 was obtained using
the Nelder-Mead optimization algorithm [84], where the search
range of c was set to (0,80). For the allele age t0, the time point of
the first appearance of the derived allele was set to be the upper
bound of the search range.
Coalescent-based estimation
We generated allele frequency trajectories for the beneficial
allele under a range of selection coefficients s between 0 and 0.5
with 0.005 increments, performing 10’000 simulations for each
value. These frequency trajectories were produced using a Wright-
Fisher haploid model with selection as described above. For
replicate 1 of the drug-treated H1N1 strain, we calculated the
population size at each generation using the estimated census
population sizes measured at the beginning of each passage
(Table 1). Further, we assume exponential population growth for
13 generations during each passage, reaching a final population of
106 virions. We accepted those trajectories presenting a difference
between the derived allele frequency of observed and simulated
data lower than e=0.10 at all time points (from passage 3 to
passage 12).
The accepted trajectories were used to run the simulation
software msms [85] under a demographic model resembling the
experimental data (twelve consecutive passages with selection
starting at passage 4) (Figure 1 and Table 1). msms is a coalescent
simulation program that incorporates time-sampled data [86] and
conditional coalescent on frequency trajectories. msms was used to
obtain the tree length starting at passage 3 (drug free) and finishing
at the end of the experiment (passage 12). We used a search range
for the mutation rate m between 1029 and 1022 and computed the
probability of observing the total number of segregating sites
present in the whole genome of H1N1 for replicate 1 (9666
segregating sites) given the total tree length multiplied by the
mutation rate using binomial sampling. Finally, we computed the
probability of observing the real data given the simulated by
integrating over all possible genealogies G:
p(DDh,m)~
ð
p(DDh,m,G)p(GDh,m)dG
~
ð
p(DDm,G)p(GDh)dG
^
ð
p(S, f Dm,G)p(GDh)dG
~
ð
p(SDf ,m,g)p(f Dm,h)p(GDh)dG
&
1
N
X
i
p(SDm,g)I( fi{fj jve)
where D refers to the total number of segregating sites (S) and the
derived allele frequency of the beneficial allele (f). h represents the
demographic model and m the mutation rate. fi and f respectively
represent the frequency of the simulated and observed beneficial
allele, and I the indicator function.
Estimation of the shape of the distribution of fitness
effect
Mathematica 9.0 was used to fit the distributions using numerical
maximization of the log-likelihoods of the data under the given
distribution. The probability density functions resulting from
weighting the original distribution with the fixation probability of a
beneficial mutation, 1-e22s, and subsequent normalization were
performed as follows:
Contending half-normal distribution:
f (s)~
2se{
{x2s2
p (1{e{2x)
p(1{e
p
s2 )Erfc(
ﬃﬃﬃ
p
p
s
)
where Erfc(x) is the complementary error function, for x§0:
Scaled beta distribution:
f (s)~
x(m{x)b{1
Beta(2,b)mbz1
for 0ƒxƒm
where Beta(a,b) is the Euler beta function.
Contending generalized Pareto distribution:
f (s)~
(1z
kx
t
){
kz1
k (1{e{2x)
Ð{tk
0
(1z
kx
t
){
kz1
k (1{e{2x)
for 0ƒxƒ{ t
k
, if kv0,
2t{1
2t2
e{
2tz1
t x(1{e2x) for x§0, if k~0,
(1z
kx
t
){
kz1
k (1{e{2x)Ð?
0
(1z
kx
t
){
kz1
k (1{e{2x)
for x§0, if kw0
8>>>>>>>><
>>>>>>>>:
In order to evaluate the confidence in the estimated parameters,
a weighted likelihood bootstrap was performed as described by
Newton and Raftery [62]. 1000 weighted likelihoods were
obtained according to Equation 1 therein, with weights being
randomly drawn from a uniform Dirichlet distribution. For the
scaled beta distribution, the boundary parameter s0 was limited to
values smaller or equal to 1 to ensure successful maximization, and
if the estimated MLE yielded s0 = 1, we concluded that no distance
to the optimum could be obtained – in fact, in all tested cases in
the presence of oseltamivir the likelihood appeared to increase
monotonically as s0 approached infinity (results not shown).
Structural analysis
Residues that mutated during the course of the experiments
were highlighted on the structures of HA, NA and M1. The
structure for HA of Influenza A/Brisbane/59/2007 has been
generated via molecular modeling [87] and was used in this study.
Closely related NA (PDB 3CL0) and M1 (PDB 1EA3) structures
were also used. Images were generated in PyMol.
Supporting Information
Figure S1 Genetic diversity of H1N1 throughout the experi-
ment. The genetic diversity measured as the average expected
heterozygosity in passages 4 to 12 of our experiment in the absence
(dotted line) or presence (dashed line) of oseltamivir.
(PDF)
Figure S2 Site frequency spectra (SFS) of H1N1 populations
during the experiment. The SFS at passages 4 (A and B) and 12 (C
and D) is shown in the absence (A and C) and presence (C and D)
of oseltamivir.
(PDF)
Figure S3 ABC correlation plot. The correlation between the
simulated selection coefficients s and the two statistics (Fs9i (A) and
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Fs9d (B)) used in our ABC method. Note that Figure 4A is showing
the same correlation using colors.
(PDF)
Figure S4 Frequency of identified beneficial mutations in
natural populations. The allele frequency in natural populations
from the NCBI Influenza Virus Resource database for the
significant mutations identified to be under selection - plotted
between years 2004 and 2010.
(PDF)
Figure S5 Cross validation of our Ne-based ABC method. The
true vs. the estimated values of Ne (A and C) and s (B and D) for the
1000 simulated data used to validate our ABC procedure. We used
similar parameters to our real data: sample size = 1000, Ne= 176
and initial allele frequencies of 1/Ne. We simulated a population of
constant size (A and B) or experiencing recurrent bottleneck
(N= 23) followed by exponential growth (up to N= 106) mimicking
our experiment (C and D). Error bars in B and D represent the
10% and 90% quantiles over the 1000 replicates. The red dot in A
and C and the red line in B and D indicate the true value.
(PDF)
Figure S6 SNPs with poor fit to the Wright-Fisher model. The
minor allele frequency trajectories of all SNPs identified as not
fitting the Wright-Fisher model in the absence and presence of
oseltamivir respectively in A and B. The horizontal dotted red line
indicates the start of oseltamivir treatment (see Figure 1).
Trajectories are represented in dashed lines if a second SNP was
significant within the same segment. For each SNP, the name of
the segment, the position of the SNP, the nucleotide increasing in
frequency, and the estimated selection coefficients with our Ne-
based ABC method are indicated in the top left corner of A and B.
(PDF)
Figure S7 Ne-based Approximate Bayesian Computation for
SNP PB1 33 (K11). For 10’000 simulated trajectories (out
of the 100’000 simulations performed), we plot in A the values
of the statistics Fs9i and Fs9d with colors corresponding to the
selection coefficients s, as well as the values calculated for the real
trajectory of the poor fitting PB1 33 (K11) mutation (see Figure S5)
in black. We indicate the region corresponding to the best 1%
retained simulations with a dashed line, and we plot the corres-
ponding two-dimensional posterior distribution for s and Ne in B.
We clearly see in A the inability of the model to generate
simulations near the observed data, with the black dot being
outside the retained regions defined by the dashed lines.
(PDF)
Figure S8 Evidence of positive selection in the H1N1 genome in
the absence and presence of oseltamivir for replicated data. We
plot the Bayesian P-values of each SNP in log scale in the absence
and presence of oseltamivir in A and C, respectively. The
horizontal red lines are genome-wide significance thresholds of
P= 0.01. The eight segments are separately color-coded, a scheme
which is maintained in all panels and in Figure 3. Significant
nonsynonymous mutations are represented with triangles. We plot
the minor allele frequency trajectories of all significant SNPs over
the replicated experiment in the absence and presence of
oseltamivir respectively in B and D. The horizontal dotted red
line indicates the start of oseltamivir treatment (see Figure 1). All
colors and line styles match those in Figure 1. Trajectories are
represented as dashed lines when a second SNP was significant in
a segment, and dotted lines for a third SNP. For each significant
SNP, the name of the segment, the position of the SNP, the
nucleotide increasing in frequency, and the estimated selection
coefficients with our Ne-based ABC method are indicated in the
top left corner of B and D.
(PDF)
Figure S9 Maximum likelihood for the DFE fit. The boxplots
show the distribution of the maximum log-likelihoods obtained
from 1000 samples of a weighted likelihood bootstrap in the
absence and presence of oseltamivir in A and B, respectively.
(PDF)
Figure S10 Genome wide sequence coverage data for samples
used in this study. The coverage in log scale for our four
experiments at passages 0, 6 and 12 (see Figure 1).
(PDF)
Figure S11 Estimated Ne when excluding segments. The posterior
distribution obtained for Ne using step 1 of our ABC algorithm when
excluding each segment one by one in the absence (A) and presence
(B) of oseltamivir. Segment colors match those in Figure 3 and S8.
(PDF)
Table S1 Estimated selection coefficients for the replicate
experiment. Comparison of Ne-ABC and Malaspinas et al. [32]
estimates of s for the significant trajectories under selection for the
replicate experiment. Bold indicates nonsynonymous mutations.
We indicate the nucleotide corresponding to the minor allele, with
its initial frequency at the beginning of the experiment in the
absence of oseltamivir, or at passage 4 when drug treatment began
(see Figure 1). For the Ne-ABC method, we give the 99% highest
posterior density intervals (HPDIs) in brackets.
(PDF)
Table S2 Viral passaging and drug concentration data for
samples used in this study.
(PDF)
Table S3 Genome wide sequence coverage data for samples
used in this study.
(PDF)
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